Comparing CMR Mapping Methods and Myocardial Patterns Toward Heart Failure Outcomes in Nonischemic Dilated Cardiomyopathy
Tomás Vita(Brigham and Women's Hospital), Raymond Y. Kwong(Brigham and Women's Hospital), Ron Blankstein(Brigham and Women's Hospital), Eri Watanabe(Brigham and Women's Hospital), Yuna L. Choi(Brigham and Women's Hospital), Michael L. Steigner(Brigham and Women's Hospital), François‐Pierre Mongeon(Montreal Heart Institute), Ayaz Aghayev(Brigham and Women's Hospital), Christoph Gräni(University of Bern), Otávio R. Coelho‐Filho(Brigham and Women's Hospital), Michael Jerosch‐Herold(Brigham and Women's Hospital), Carlos Henrique Reis Esselin Rassi(Brigham and Women's Hospital), Kathleen Cheng(Brigham and Women's Hospital), Siddique Abbasi(Brigham and Women's Hospital), Tomas G. Neilan(Duke Medical Center), Michael M. Givertz(Brigham and Women's Hospital), Kyoichi Kaneko(Brigham and Women's Hospital), Hoshang Farhad(Brigham and Women's Hospital), Ethan J. Rowin(Brigham and Women's Hospital)
Cited by 109
Related Papers
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k
Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2020|1k
Intravenous Nesiritide, a Natriuretic Peptide, in the Treatment of Decompensated Congestive Heart Failure
|New England Journal of Medicine|2000|908
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
|European Heart Journal|2021|589